GLP-1 Medications Explained: Benefits, Risks and Safer Decisions

Editorially reviewed by: A to Zen Therapies Editorial Team in accordance with our Editorial Policy.

GLP-1 and dual GIP/GLP-1 medicines are prescription treatments that require individual assessment, careful dose increases and ongoing monitoring.

Interest in GLP-1 medications has grown rapidly because these medicines can improve blood-glucose control and support clinically meaningful weight loss in appropriately selected patients.

They are not interchangeable wellness products or cosmetic shortcuts. Different medicines have different licensed uses, doses, contraindications and side-effect profiles. A medicine prescribed for type 2 diabetes is not automatically authorised for weight management, even when it contains a similar active ingredient.

Understanding the differences between licensed injections, oral formulations, compounded products and products marketed as “GLP-1 patches” can help people avoid unsafe or misleading options.

Quick Answer

GLP-1 receptor agonists mimic the effects of a natural gut hormone involved in appetite and blood-glucose regulation. They may increase fullness, reduce food intake, slow stomach emptying and stimulate insulin release when blood glucose is elevated.

Semaglutide and liraglutide act primarily through GLP-1 receptors. Tirzepatide acts through both GIP and GLP-1 receptors. These are prescription medicines with genuine clinical evidence, but they are not suitable for everyone.

Products promoted as over-the-counter “GLP-1 patches” are not equivalent to approved medicines and have not been shown to deliver a therapeutic dose of semaglutide, tirzepatide or another licensed GLP-1 medicine.

⭐ What Are GLP-1 Medications?

GLP-1 medications are prescription treatments that imitate or enhance hormonal signals involved in blood-glucose control, digestion, appetite and fullness. Some are authorised for type 2 diabetes, some for weight management and some for both uses under different product names and eligibility criteria.

Key Takeaways

• GLP-1 medications are prescription medicines—not ordinary supplements.

• Semaglutide and liraglutide are GLP-1 receptor agonists.

• Tirzepatide acts on both GIP and GLP-1 receptors.

• Brand names containing related ingredients can have different licensed uses.

• Treatment normally begins at a low dose that is increased gradually.

• Nausea, vomiting, diarrhoea and constipation are common side effects.

• Severe persistent abdominal pain requires urgent medical assessment.

• Consumer “GLP-1 patches” are not equivalent to authorised medicines.

• Medicines should not be purchased through social media, beauty salons or unregulated sellers.

• Weight regain can occur after treatment stops, making long-term planning important.

Table of Contents

1. How GLP-1 Medications Work

2. Which Medicines Are Used?

3. Who May Be Eligible?

4. Do GLP-1 Patches Work?

5. Expected Benefits and Limitations

6. Common Side Effects

7. Injections Compared With Oral Medication

8. Choosing a Safe Provider

9. Supporting Health During Treatment

10. Frequently Asked Questions

How GLP-1 Medications Work

Glucagon-like peptide-1 is a hormone released by the digestive system after eating. It forms part of a wider network controlling appetite, digestion and blood glucose.

Depending on the medicine, GLP-1-based treatments may:

• Stimulate insulin release when blood glucose is elevated

• Reduce glucagon secretion

• Slow gastric emptying

• Increase feelings of fullness

• Reduce appetite and food intake

• Support improved blood-glucose control

The World Health Organization’s GLP-1 overview explains that these medicines can support weight loss but should form part of comprehensive care that also addresses nutrition, physical activity and long-term follow-up.

Not everyone responds in the same way. Appetite changes, weight loss, glucose improvements and side effects vary between individuals.

Which Medicines Are Used?

The term “GLP-1” is often used loosely to describe several related medicines. It is important to distinguish their active ingredients, brands and licensed purposes.

Semaglutide

Semaglutide is a GLP-1 receptor agonist. In the UK:

• Ozempic is authorised for type 2 diabetes.

• Wegovy is authorised for weight management in eligible patients.

• Rybelsus is an oral semaglutide product authorised for type 2 diabetes.

These brands should not be substituted without advice simply because they contain the same active ingredient. Their doses, delivery methods and licensed indications differ.

Liraglutide

Liraglutide is another GLP-1 receptor agonist. Different liraglutide brands have been used for type 2 diabetes and weight management, with different dosing instructions.

Tirzepatide

Tirzepatide is a dual GIP and GLP-1 receptor agonist. It should not be described as acting only on GLP-1.

NICE recommends tirzepatide as an option for certain adults with overweight or obesity alongside a reduced-calorie diet and increased physical activity, subject to clinical eligibility and NHS implementation arrangements.

Other GLP-1 Medicines

Other medicines in this wider class may be used for type 2 diabetes without being authorised for weight management. A prescriber should explain:

• Why a particular medicine is being recommended

• Its licensed indication

• How and when to take it

• What benefits are realistic

• Which adverse effects require attention

• How progress will be reviewed

Who May Be Eligible?

GLP-1-based weight-management treatment is not intended for anyone seeking a small cosmetic change. Eligibility can depend on:

• BMI

• Weight-related health conditions

• Previous weight-management support

• Type 2 diabetes status

• Current medicines

• Pregnancy intentions

• Digestive or pancreatic history

• Local NHS commissioning arrangements

• The licensed indication of the product

The NICE guide to medicines for overweight and obesity explains how options such as tirzepatide, semaglutide and liraglutide fit within wider clinical care.

BMI is not a complete measure of health and may require interpretation for different ethnic groups. A proper assessment should also consider blood pressure, blood glucose, cholesterol, mobility, sleep, medicines, eating behaviour and individual goals.

If progress has been difficult despite sustainable changes, read What Should You Do If You Are Struggling to Lose Weight? for possible underlying factors and questions to discuss with a GP.

Do GLP-1 Patches Work?

People searching for needle-free alternatives often ask how do GLP 1 patches work. This question requires an important distinction between experimental drug-delivery research and consumer wellness patches sold online.

Consumer GLP-1 Patches

Products marketed as “natural GLP-1 patches” frequently contain plant extracts, vitamins, caffeine or other supplement ingredients rather than semaglutide, liraglutide or tirzepatide.

These products:

• Are not equivalent to prescription GLP-1 medicines

• Have not demonstrated comparable effects in large clinical trials

• May not contain an actual GLP-1 receptor agonist

• May provide incomplete ingredient or dosage information

• Cannot be assumed to control diabetes or produce medical weight loss

The phrase “GLP-1 patch” may therefore describe a marketing concept rather than the presence of an authorised GLP-1 medicine.

Why Ordinary Patches Cannot Simply Replace Injections

The skin’s outer layer is an effective barrier. Large peptide medicines do not readily cross it in clinically useful quantities through an ordinary adhesive patch.

Researchers are investigating microneedles, nanoparticles and other specialised systems for delivering peptide medicines through the skin. A review of microneedle-mediated protein and peptide delivery shows that this is a genuine field of pharmaceutical research.

However, experimental technologies should not be confused with over-the-counter stickers sold as weight-loss supplements. Research in cells, animals or early prototypes does not establish that a consumer product safely delivers a therapeutic dose in humans.

📊 Evidence Snapshot

• Licensed GLP-1 and dual GIP/GLP-1 medicines have been evaluated in controlled clinical trials.

• Consumer GLP-1 patches do not have equivalent clinical evidence.

• Standard adhesive patches cannot be assumed to deliver large peptide medicines through intact skin.

• Experimental microneedle delivery remains different from an authorised medicine available through a pharmacy.

• Herbal ingredients marketed as “GLP-1 supporting” do not reproduce the pharmacological action of semaglutide or tirzepatide.

A product using “GLP-1” in its marketing is not necessarily a GLP-1 receptor agonist or an authorised medicine.

Expected Benefits and Limitations

GLP-1-based medicines can be effective for eligible patients. Depending on the medicine and condition, benefits may include:

• Improved blood-glucose control

• Reduced appetite

• Clinically meaningful weight loss

• Improvement in some metabolic risk markers

• Reduced cardiovascular risk for certain patient groups and products

Results seen in clinical trials are averages—not promises. Individual outcomes may differ because of adherence, dose tolerance, health conditions, lifestyle, access and biological variation.

Medication Does Not Replace Nutrition

Reduced appetite can make it harder for some people to consume enough protein, fibre, fluid and essential nutrients. An appropriate plan should help preserve muscle and nutritional adequacy rather than focusing only on the number on the scale.

Useful priorities may include:

• Regular sources of protein

• Fruit and vegetables tolerated comfortably

• Suitable fibre intake

• Adequate fluid

• Resistance exercise where appropriate

• Monitoring excessive or unusually rapid weight loss

Our guide to healthy fats and nutrition explains how unsaturated fats can contribute to a balanced dietary pattern without relying on highly restrictive rules.

Medication Does Not Replace Mental-Health or Eating-Disorder Care

Loss-of-control eating, binge eating, severe restriction and body-image distress require compassionate assessment. Appetite suppression alone may not resolve the psychological or behavioural factors involved.

Read Binge Eating: There Is Help Out There for information about recognising symptoms and seeking appropriate support.

Is GLP-1 Treatment Long Term?

Obesity is increasingly understood as a chronic, relapsing condition rather than a simple failure of willpower. The WHO’s 2025 guideline positions GLP-1-based therapies as potential long-term treatments within comprehensive obesity care.

Clinical trials have found that some participants regain weight after medication is withdrawn. In the STEP 1 trial extension, participants regained a substantial proportion of the weight previously lost after semaglutide treatment ended.

This does not mean that everyone must continue indefinitely. It means that stopping should be planned with the prescriber rather than treated as an abrupt end to care.

A long-term plan may consider:

• The reason for stopping

• Side effects

• Costs and access

• Appetite returning

• Sustainable eating patterns

• Physical activity and muscle maintenance

• Psychological support

• Monitoring blood glucose or other markers

• Alternative treatments where appropriate

Do not suddenly stop a diabetes medicine without discussing the consequences with the prescriber.

Common Side Effects

The NHS semaglutide guide lists common effects including:

• Nausea

• Vomiting

• Diarrhoea

• Constipation

• Tiredness

• Injection-site reactions

Indigestion, abdominal discomfort and reduced appetite may also occur with some medicines. Side effects are often more noticeable when treatment begins or the dose increases.

The prescriber may recommend:

• Smaller meals

• Eating more slowly

• Stopping when comfortably full

• Avoiding unusually rich meals when symptoms are present

• Drinking regularly

• Delaying dose increases when clinically appropriate

Do not alter the dose or schedule without professional advice.

Regular follow-up allows the prescriber to review side effects, nutritional intake, other medicines and whether treatment remains appropriate.

Serious Symptoms Requiring Prompt Assessment

Seek urgent medical advice for:

• Severe and persistent abdominal pain

• Abdominal pain spreading through to the back

• Repeated vomiting or inability to keep fluids down

• Symptoms of serious dehydration

• A swollen abdomen with severe constipation or vomiting

• Yellowing of the skin or eyes

• Severe allergic symptoms

• Sudden or significant vision changes

• Symptoms of severe hypoglycaemia

In January 2026, the MHRA strengthened warnings about acute pancreatitis for GLP-1 and dual GIP/GLP-1 medicines. Acute pancreatitis is uncommon but can be severe.

Low blood glucose is particularly relevant when these medicines are used alongside insulin or sulfonylureas. The diabetes-treatment plan may need adjustment by the clinical team.

Suspected medicine side effects can also be reported through the MHRA Yellow Card scheme.

Pregnancy, Contraception and Breastfeeding

GLP-1-based medicines are not recommended during pregnancy, and individual products require different periods between stopping treatment and trying to conceive.

The MHRA guidance on GLP-1 medicines and contraception explains that weight-loss injections must not be used during pregnancy, while trying to become pregnant or while breastfeeding.

Tirzepatide can affect the absorption of oral contraception during treatment initiation and after dose increases. People using oral contraception should follow the product-specific instructions and seek advice from the prescriber or pharmacist.

Do not stop prescribed treatment or contraception without discussing a safe plan.

Surgery, Sedation and Medical Procedures

GLP-1 and dual GIP/GLP-1 medicines slow gastric emptying. This can leave food in the stomach even after someone has followed ordinary fasting instructions.

Tell the surgical, endoscopy and anaesthetic teams that you use one of these medicines. The MHRA warns about possible aspiration during general anaesthesia or deep sedation.

Do not independently skip or stop doses before a procedure. The clinical team should provide instructions based on the medicine, symptoms, procedure and current guidance.

Injections Compared With Oral Medication

Injectable Medicines

Many GLP-1 medicines are supplied in pre-filled pens. Depending on the product, injections may be given daily or weekly.

Benefits may include:

• Infrequent dosing with weekly products

• Established dosing schedules

• Avoiding gastrointestinal absorption barriers

Possible disadvantages include:

• Discomfort with needles

• Injection-site reactions

• Storage requirements

• The need to learn correct pen use

Never share an injection pen, even if the needle is changed.

Oral Semaglutide

Oral semaglutide uses a specialised absorption enhancer called SNAC to help a small amount of the peptide pass through the stomach lining. It is not simply an injectable medicine placed inside an ordinary tablet.

It must be taken according to detailed instructions relating to fasting, water and waiting before food or other medicines. Failure to follow these instructions can affect absorption.

The existence of an oral formulation does not prove that an ordinary skin patch can deliver the same medicine.

💡 Expert Tip: Always identify the active ingredient, brand, dose and licensed purpose. “Ozempic,” “Wegovy,” “Mounjaro,” “Saxenda” and “Rybelsus” are not interchangeable names for one universal weight-loss product.

Choosing a Safe Provider

The MHRA advises against buying GLP-1 medicines through social media, beauty salons or any seller that supplies them without a proper clinical consultation.

A suitable provider should:

• Use a registered prescriber

• Assess medical history and current medication

• Confirm the treatment’s indication

• Explain benefits, limitations and adverse effects

• Provide a named, licensed product

• Supply through a registered pharmacy

• Explain storage and administration

• Offer follow-up and dose review

• Provide a route for reporting problems

Warning signs include:

• Guaranteed weight loss

• No medical questionnaire or consultation

• Powdered products requiring home mixing

• Claims that a product is “identical” to an authorised medicine

• Sales through social-media messages

• Pressure to buy several months at once

• No identifiable prescriber or pharmacy

• Products labelled “research use only”

The FDA similarly warns about unapproved GLP-1 products because they have not undergone the same review for safety, effectiveness and quality.

Supporting Health During Treatment

Effective care should extend beyond prescribing and weighing. Follow-up may consider:

• Side effects

• Hydration

• Nutritional intake

• Muscle strength

• Blood glucose

• Blood pressure

• Relevant blood tests

• Mood and eating behaviour

• Changes in other medicines

• Plans for maintenance or discontinuation

Readers interested in metabolic monitoring can read How Blood Biomarkers Reveal the Impact of Your Diet.

Physical activity should begin at an appropriate level and increase gradually. Our guide to setting realistic fitness goals offers a more sustainable alternative to extreme exercise targets.

How A to Zen Therapies Can Help

A to Zen Therapies does not prescribe GLP-1 medicines, diagnose obesity or provide medical weight-management treatment.

Complementary services may support relaxation or temporary relief from everyday muscular tension alongside an appropriate healthcare plan. People managing stress may consider a relaxing massage in London.

Radiofrequency body sculpting is a cosmetic body-contouring treatment. It does not treat obesity, reproduce GLP-1 effects or provide medical weight loss. Massage and lymphatic-drainage treatments also do not remove body fat or prevent medication side effects.

Tell the therapist about GLP-1 treatment, significant appetite changes, dehydration, dizziness, abdominal symptoms and other medicines before receiving complementary treatment.

Continue Exploring Weight and Metabolic Health

Sustainable weight management may involve nutrition, physical activity, sleep, emotional wellbeing and medical care. Explore our Nutrition Hub, Hormone Health Hub, Exercise and Rehabilitation Hub, Mental Wellbeing Hub, Women’s Health Hub and Men’s Health Hub.

Frequently Asked Questions

Are all GLP-1 medications weight-loss medicines?

No. Some are authorised for type 2 diabetes, some for weight management and some have different indications under different brands.

Is tirzepatide a GLP-1 medication?

Tirzepatide is commonly grouped with GLP-1 medicines, but it acts on both GIP and GLP-1 receptors.

Do GLP-1 patches contain semaglutide?

Consumer products marketed as GLP-1 patches commonly contain supplements or botanical ingredients rather than authorised semaglutide. Check the complete ingredient list and regulatory status.

Can an ordinary patch deliver GLP-1 medication?

No authorised consumer skin patch currently replaces approved injections or oral medication. Specialised microneedle technologies remain an area of pharmaceutical research.

Are GLP-1 medicines safe?

They can provide important benefits for eligible patients but also cause adverse effects. Safety depends on the medicine, health history, other treatments and appropriate monitoring.

How quickly do GLP-1 medicines work?

Appetite or blood-glucose changes may begin before the full weight effect becomes apparent. Doses are usually increased gradually, and individual responses vary.

Can I switch between Ozempic, Wegovy and Mounjaro?

Not without professional advice. They have different active ingredients, strengths, indications and dosing schedules.

Will I regain weight after stopping?

Some people regain a significant amount of weight after stopping. A maintenance plan should be discussed with the prescriber before treatment ends.

Can I take a GLP-1 medicine while pregnant?

No. These medicines are not recommended during pregnancy. Product-specific guidance applies to contraception and the interval before conception.

What symptoms could indicate pancreatitis?

Severe, persistent abdominal pain, particularly when it spreads to the back and occurs with nausea or vomiting, requires urgent medical assessment.

Should I tell an anaesthetist that I use a GLP-1 medicine?

Yes. Delayed stomach emptying can affect aspiration risk during general anaesthesia or deep sedation.

Are compounded or powder products the same as approved

medicines?

No. Products requiring home mixing or supplied outside regulated pathways should not be assumed to have the same quality, dosing accuracy or evidence.

References

• World Health Organization — GLP-1 Therapies and Obesity

• WHO — Global Guideline on GLP-1 Medicines for Obesity

• NICE — Medicines for Managing Overweight and Obesity

• NICE — Tirzepatide Recommendations

• NHS — Semaglutide

• MHRA — What You Need to Know About GLP-1 Medicines

• MHRA — Strengthened Pancreatitis Warnings

• MHRA — GLP-1 Medicines and Anaesthesia

• STEP 1 Extension — Weight Regain After Semaglutide Withdrawal

• FDA — Concerns With Unapproved GLP-1 Products